Zoetis Inc. (NYSE:ZTS) Holdings Cut by Everett Harris & Co. CA

Everett Harris & Co. CA decreased its stake in Zoetis Inc. (NYSE:ZTS) by 6.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 4,803 shares of the company’s stock after selling 306 shares during the quarter. Everett Harris & Co. CA’s holdings in Zoetis were worth $948,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BOS Asset Management LLC raised its holdings in shares of Zoetis by 3.2% during the 2nd quarter. BOS Asset Management LLC now owns 1,684 shares of the company’s stock valued at $290,000 after purchasing an additional 53 shares in the last quarter. Enterprise Financial Services Corp raised its holdings in shares of Zoetis by 2.3% during the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock valued at $407,000 after purchasing an additional 55 shares in the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Zoetis by 0.4% during the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock valued at $2,210,000 after purchasing an additional 57 shares in the last quarter. MJP Associates Inc. ADV raised its holdings in shares of Zoetis by 4.8% during the 3rd quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company’s stock valued at $222,000 after purchasing an additional 58 shares in the last quarter. Finally, TFC Financial Management Inc. raised its holdings in shares of Zoetis by 3.3% during the 3rd quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock valued at $334,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS traded up $0.61 during midday trading on Thursday, hitting $169.12. The company had a trading volume of 3,395,584 shares, compared to its average volume of 2,739,733. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The stock has a market cap of $77.43 billion, a price-to-earnings ratio of 33.36, a P/E/G ratio of 2.53 and a beta of 0.87. The firm has a fifty day simple moving average of $185.92 and a two-hundred day simple moving average of $182.24. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.15 earnings per share. Equities analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.02%. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $191.43, for a total transaction of $176,689.89. Following the sale, the executive vice president now directly owns 17,569 shares in the company, valued at approximately $3,363,233.67. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 2,209 shares of company stock worth $408,453. Corporate insiders own 0.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. Jefferies Financial Group reiterated a “buy” rating and issued a $230.00 target price on shares of Zoetis in a research note on Tuesday, December 19th. The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. BNP Paribas began coverage on shares of Zoetis in a research note on Thursday, December 7th. They issued an “outperform” rating and a $237.00 target price on the stock. Finally, Stifel Nicolaus raised their target price on shares of Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, January 12th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $224.33.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.